NCT02254772 - A Phase I/II Study of Intratumoral Injection of SD-101 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 10, 2016

Study Completion Date

January 26, 2017

Conditions

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaSplenic Marginal Zone Lymphoma

Interventions

BIOLOGICAL

Ipilimumab

A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.

DRUG

SD-101

Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.

RADIATION

Radiation therapy

Undergo low-dose radiation therapy to 1 site of disease

Trial Locations (1)

94305

Stanford University Hospitals and Clinics, Stanford

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Robert Lowsky

OTHER